Sales, Supply and Business Continuity Risks from COVID-19

「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

「There have been no significant changes in the occurrence of the major risks that management recognizes as potentially having a material impact on the financial position, operating results or cash flows of the consolidated companies, among the matters relating to the business and accounting conditions described in this quarterly report, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year. With respect to the impact of COVID-19 on full-year results, we believe the impact will be limited if economic-priority measures continue under the government’s current infection-control policy. However, in consideration of the potential further spread of COVID-19, we will continue to closely monitor its impact on results.」

「During the second-quarter cumulative consolidated period, there were no significant changes in the occurrence of major risks that management recognises as potentially having a material impact on the financial condition, results of operations or cash flows of the consolidated companies, among the matters concerning business conditions, accounting and other matters described in the quarterly report, or in the section entitled “Business and Other Risks” in the securities report for the previous fiscal year. The impact of COVID-19 on full-year results is also expected to be limited if economic-priority measures based on the government's current infection-control policy continue. However, in view of the possibility of a further spread of COVID-19, the company will continue to closely monitor its impact on results.」

「During the first-quarter cumulative consolidated period, there were no significant changes in the occurrence of major risks that management recognises as potentially having a material impact on the financial condition, results of operations or cash flows of the consolidated companies, among the matters concerning business conditions, accounting and other matters described in the quarterly report, or in the section entitled “Business and Other Risks” in the securities report for the previous fiscal year. The impact of COVID-19 on full-year results is also expected to be limited if economic-priority measures based on the government's current infection-control policy continue. However, in view of the possibility of a further spread of COVID-19, the company will continue to closely monitor its impact on results.」

「As stated in “2. Business and Other Risks” under “II. Business Conditions,” COVID-19 had no direct impact during the consolidated fiscal year under review. Looking ahead, assuming that economic-priority measures based on the government's current infection-control policy continue, we believe that the likelihood of a material impact on research and development and other activities is low.」

「In addition, overseas revenue declined due in part to the impact of the resurgence of COVID-19 in the Asia-Pacific region.」

「The impact of COVID-19 on full-year results is expected to be limited if the current downward trend in infections continues. However, in view of the possibility of a further spread of COVID-19, we will continue to closely monitor its impact on results.」

「At the same time, delays in clinical trials caused by the fifth wave of COVID-19 and restrictions on access to research facilities have, in some cases, made it difficult to adequately meet demand for research and development.」

「During the consolidated fiscal year, delays in research plans, including large-scale human studies, resulted in scheduled orders being postponed, and orders declined from the previous consolidated fiscal year.」

「Against this backdrop, the Group sought to expand orders in the metabolomics business through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. However, during the third quarter consolidated accounting period, both orders and sales declined because scheduled orders were postponed and measurement samples were delayed, resulting in lower revenue for the third quarter cumulative consolidated period as well.」

「During the second-quarter cumulative consolidated period, there were no significant changes in the occurrence of major risks that management recognises as potentially having a material impact on the financial condition, results of operations or cash flows of the consolidated companies, among the matters concerning business conditions, accounting and other matters described in the quarterly report, or in the section entitled “Business and Other Risks” in the securities report for the previous fiscal year. The company will continue to closely monitor the future impact of COVID-19 on its business.」

「During the first-quarter cumulative consolidated period, there were no significant changes in the occurrence of major risks that management recognises as potentially having a material impact on the financial condition, results of operations or cash flows of the consolidated companies, among the matters concerning business conditions, accounting and other matters described in the quarterly report, or in the section entitled “Business and Other Risks” in the securities report for the previous fiscal year. The company will continue to closely monitor the future impact of COVID-19 on its business.」

「Although COVID-19 and other factors have not had a material impact on the results for the consolidated fiscal year under review, a prolonged resolution of the outbreak could affect the Group's results and future business development through stagnation of sales activities caused by the cancellation or postponement of academic conferences, delays in obtaining measurement samples, and disruption to operations caused by employees contracting the disease.」